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Abstract
Background—Studies examining the association of dialysate potassium concentration and 
mortality in hemodialysis patients show conflicting findings. We hypothesized that low dialysate 
potassium concentrations are associated with higher mortality, particularly in patients with high 
pre-dialysis serum potassium concentrations.
Methods—We evaluated 624 hemodialysis patients from the prospective Malnutrition, Diet, and 
Racial Disparities in Kidney Disease study recruited from 16 outpatient dialysis facilities over 
2011-15 who underwent protocolized collection of dialysis treatment characteristics every six 
months. We examined the association of dialysate potassium concentration, categorized as 1, 2, 
and 3mEq/L, with all-cause mortality risk in the overall cohort, and stratified by pre-dialysis 
serum potassium (<5mEq/L vs. ≥5mEq/L) using case-mix adjusted Cox models.
Results—In baseline analyses, dialysate potassium concentrations of 1mEq/L were associated 
with higher mortality, whereas concentrations of 3mEq/L were associated with similar mortality in 
the overall cohort (reference: 2mEq/L): adjusted HRs (aHRs) (95% CI) 1.70 (1.01-2.88) and 0.95 
(0.64-1.39), respectively. In analyses stratified by serum potassium, baseline dialysate potassium 
concentrations of 1mEq/L were associated with higher mortality in patients with serum potassium 
≥5mEq/L but not in those with serum potassium <5mEq/L: aHRs (95% CI) 2.87 (1.51-5.46) and 
0.74 (0.27-2.07), respectively (p-interaction=0.04). These findings were robust with incremental 
adjustment for serum potassium, potassium-binding resins, and potassium-modifying medications.
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Conclusion—Low (1mEq/L) dialysate potassium concentrations were associated with higher 
mortality, particularly in hemodialysis patients with high pre-dialysis serum potassium. Further 
studies are needed to identify therapeutic strategies that mitigate inter-dialytic serum potassium 
accumulation and subsequent high dialysate-serum potassium gradients in this population.
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Introduction
Regulation of serum potassium is essential to health and survival, given the potent 
association between hyperkalemia and hypokalemia with cardiovascular complications, 
particularly ventricular arrhythmias.[1–6] Daily potassium intake typically ranges between 
60 to 150mmol in the typical Western diet, with 92% and 8% excreted in urine and stool, 
respectively, in order to maintain total body potassium homeostasis.[7] In the context of 
normal kidney function, serum potassium levels can be maintained within normal ranges 
with up to a ten-fold higher intake of potassium, albeit with gradual increases in 
consumption. However, as kidney function declines, there is a compensatory increase in the 
fecal excretion of potassium up to a certain threshold below which hyperkalemia eventually 
ensues. [8, 9]
While it is well established that hemodialysis is a critical intervention for maintaining 
potassium homeostasis among end-stage renal disease patients, there remains wide debate 
regarding the appropriate prescription of dialysate potassium concentrations in this 
population. Although clinical practice guidelines do not currently provide recommendations 
on the prescription of dialysate potassium, many clinicians apply a “Rule of 7’s” in which 
the sum of a patient’s serum potassium and dialysate potassium concentrations should 
approximate 7mEq/L.[10] However, there is limited data supporting these methods of 
dialysate potassium concentration selection.
There is particular controversy regarding the safety of low dialysate potassium 
concentrations utilized in the maintenance hemodialysis population, particularly among 
patients with high pre-dialysis serum potassium levels. To date, several studies have 
observed that patients prescribed low dialysate potassium concentrations of 0mEq/L and 
1mEq/L experience higher all-cause and cardiovascular mortality risk.[10–13] Adding to 
these aforementioned uncertainties, there has also been concern that abrupt changes in 
potassium kinetics during hemodialysis ensuing from a high serum-to-dialysate potassium 
gradient may increase risk of cardiovascular morbidity and mortality. For example, serum 
potassium levels decline most precipitously during the first two to three hours of 
hemodialysis, and following completion of dialysis treatment. In addition, while the vast 
majority of the body’s potassium is intracellular (98% vs. 2% stored in the intracellular vs. 
extracellular space, respectively)[4–6], dialysis has greater influence upon extracellular vs. 
intracellular potassium concentrations, post-dialysis rebound is frequently observed (i.e., 
35% and 65% attenuation in intra-dialytic serum potassium reductions within one and six 
hours after hemodialysis treatment, respectively).[8] Thus, it has been hypothesized that a 
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large differential between serum and dialysate potassium concentrations may exacerbate 
rapid changes in potassium kinetics, leading to instability in cardiac conduction and 
heightened risk of malignant arrhythmias in hemodialysis patients.[14, 15]
However, studies of the serum-to-dialysate potassium gradient and mortality in hemodialysis 
patients have shown mixed findings to date.[2, 10, 11, 16, 17] Thus, to better inform the 
field, we examined repeated measures of dialysate and serum potassium concentrations 
among a prospective multi-center cohort of hemodialysis patients in Southern California. We 
aimed to test the hypothesis that lower dialysate potassium concentrations prescribed to 
hemodialysis patients with higher serum potassium levels (i.e., high serum-to-dialysate 
potassium gradient) were associated with higher mortality risk.
Methods
Study Population
The study population was comprised of adult hemodialysis patients in the ongoing 
Malnutrition, Diet, and Racial Disparities in Chronic Kidney Disease (MADRAD) study 
(ClinicalTrials.gov study: NCT01415570), a prospective cohort study examining the 
differential association between dietary factors and nutritional status across racial and ethnic 
subgroups.[18–20] In the ongoing MADRAD study, patients undergo protocolized 
assessment of socio-demographics, comorbidities, medications, dialysis treatment 
characteristics, laboratory tests, nutritional status, and body anthropometry every six months 
(designated as study rounds).[18–20] The study population was a subcohort of MADRAD 
study patients recruited from 16 outpatient dialysis clinics in the Southern California region 
over October 2011 to February 2015, with follow up through November 2016.
Patients were included in the study provided that they had available dialysate and serum 
potassium data collected during the same round, were age 18 years or older at the time of 
study entry (i.e., date of first dialysate potassium concentration assessment), were receiving 
thrice-weekly in-center hemodialysis for at least four weeks, and signed a local institutional 
review board approved consent form. Patients were excluded if they were actively receiving 
treatment with peritoneal dialysis, had life expectancy less than six months, or were unable 
to provide consent. The study was approved by the institutional review committees of the 
Los Angeles Biomedical Research Institute at Harbor-UCLA and the University of 
California Irvine School of Medicine.
Exposure Ascertainment
The exposure of interest was the dialysate potassium concentration ascertained every six 
months by MADRAD research coordinators while patients were undergoing routine dialysis 
treatments, categorized as 1mEq/L, 2mEq/L, and 3mEq/L. In co-primary analyses, we 
evaluated the association between (1) dialysate potassium concentration and all-cause 
mortality in the overall cohort, as well as (2) dialysate potassium concentration and all-cause 
mortality stratified by serum potassium level dichotomized as less <5mEq/L versus 
≥5mEq/L. A cutoff of 5mEq/L was selected as the approximate median and mean serum 
potassium level in our study population, as well as an established threshold for higher 
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mortality risk in previous studies.[13] Serum potassium levels were performed by the 
outpatient dialysis clinics on a minimum monthly basis, and other routine dialysis laboratory 
measurements were conducted on a monthly or quarterly basis.
In primary analyses, we sought to examine the association between baseline dialysate 
potassium concentration and all-cause mortality. In secondary analyses, we examined the 
association between time-dependent dialysate potassium concentration and all-cause 
mortality, in which we examined repeated measures of time-updated dialysate potassium 
concentrations.
Socio-demographic, Comorbidity, Dialysis Treatment, and Medication Measures
Baseline socio-demographic, comorbidity, medication, and dialysis treatment data were 
collected at the time of enrollment and every six months by MADRAD research 
coordinators. We considered medication data prescribed within one year of study entry (i.e., 
date of first dialysate potassium concentration assessment) as collected by the MADRAD 
research coordinators and staff from participating dialysis units.
Body Anthropometry and Nutritional Score Measures
MADRAD research coordinators conducted measurements of body composition surrogates 
during routine hemodialysis treatments, including body mass index (BMI), subcutaneous fat 
(determined from biceps and triceps skinfold), visceral fat (determined from waist 
circumference), lean muscle mass (determined from mid-arm circumference [MAC] and 
mid-arm muscle circumference [MAMC]), and body fat percentage (measured by near-
infrared [NIR] interactance) as has been previously described.[18] Data on Subjective 
Global Assessment, a nutritional scoring tool, BMI, serum albumin, and total iron binding 
capacity were also used to estimate the Malnutrition-Inflammation Score as a proxy of 
protein-energy wasting (scores ranging from 0 to 30 with higher Malnutrition Inflammation 
Scores reflecting more severe degrees of protein-energy wasting).[21–26]
Outcome Ascertainment
All-cause mortality was the primary outcome of interest. At-risk time began the day after 
dialysate potassium concentration assessment, and patients were censored for kidney 
transplantation, transfer to a non-participating dialysis facility, peritoneal dialysis, or at the 
end of the study period (November 22, 2016). Every six months, information regarding 
mortality, censoring events, and associated dates from prior study rounds were collected 
from event forms completed by the MADRAD research coordinators and were reviewed by 
two MADRAD study nephrologists (CMR and KKZ).
Statistical Methods
Patients’ baseline characteristics stratified by baseline dialysate potassium concentrations 
were compared with ANOVA, Chi-Square, or Kruskal Wallis tests as appropriate. We first 
examined the relationship of relevant clinical characteristics with likelihood of being 
prescribed a low (1mEq/L) dialysate potassium concentration (reference: 2-3mEq/L) using 
logistic regression.
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We then estimated the association between dialysate potassium concentration and all-cause 
mortality using Cox proportional hazard models. Logistic regression and Cox proportional 
hazards models were conducted using five incremental levels of covariate adjustment:
1. Unadjusted model: Included dialysate potassium concentration;
2. Case-mix model: Covariates in the unadjusted model, as well as age (at the time 
of dialysate potassium concentration), sex, race (Black vs. Non-Black), and 
ethnicity (Hispanic vs. Non-Hispanic);
3. Case-mix+serum potassium model: Covariates in the case-mix adjusted model, 
as well as serum potassium concentration;
4. Case-mix+serum potassium+potassium-binding resins model: Covariates in the 
case-mix+serum potassium model, as well as potassium-binding resins (e.g., 
sodium polystyrene);
5. Case-mix+serum potassium+potassium-modifying medications model: 
Covariates in the case-mix+serum potassium+potassium-binding resin model, 
plus nonsteroidal anti-inflammatory drugs, potassium sparing diuretics, 
angiotensin converting enzyme inhibitors, and aldosterone receptor blockers.
We defined the case-mix adjusted model as our primary model, which forced into the model 
core socio-demographic measures. Analyses incrementally adjusted for serum potassium, 
potassium-binding resins, and potassium-modifying medications were conducted as 
secondary analyses. To determine the impact of key confounders upon estimates of the 
dialysate potassium concentration–mortality association, namely comorbidity burden and 
nutritional status/dietary compliance, we implemented an expanded case-mix+serum 
potassium+potassium-modifying medications model that further adjusted for history of 
diabetes, congestive heart failure, coronary artery disease, cerebrovascular disease, any 
cardiovascular disease, and Malnutrition Inflammation Score[22, 23, 25] as sensitivity 
analyses. The proportional hazards assumption was confirmed graphically and by 
Schoenfeld residual function testing. There were no missing covariate data except for 
Malnutrition Inflammation Score (i.e., 14% of patients with missing data), which was 
addressed using multiple imputation. Analyses were carried out using the statistical software 
Stata version 12.0 (StataCorp LP, College Station, TX) and SAS version 9.4 (SAS Institute 
Inc, Cary, NC).
Results
Cohort Description
Among 624 patients who met eligibility criteria (Supplementary Figure 1), the mean±SD 
age of the cohort was 54.5±14.5 years, among whom 43% were women; 35% were of Black 
race and 47% were of Hispanic ethnicity; and of whom 51% had underlying diabetes. At 
study entry, 8% (N=47), 72% (N=449), and 21% (N=128) were prescribed 1, 2, and 3mEq/L 
dialysate concentrations, respectively. Compared to patients who were prescribed 2mEq/L or 
3mEq/L dialysate concentrations, those prescribed 1mEq/L dialysate concentrations were 
more likely to be female and Hispanic; had longer dialysis vintage; and had higher 
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normalized protein catabolic rates (nPCR), serum phosphorus, and serum creatinine levels 
(Table 1).
Clinical Characteristics Associated with Dialysate Potassium Concentration
In case-mix adjusted logistic regression models, we observed that patients who were female; 
Hispanic; of longer dialysis vintage; and with higher nPCR, serum potassium, and serum 
creatinine levels had higher likelihood of receipt of a low (i.e, 1mEq/L) dialysate potassium 
concentration. Associations with female sex, Hispanic ethnicity, higher nPCR, and higher 
serum creatinine levels with low dialysate concentration persisted across all models of 
covariate adjustment. (Table 2).
Dialysate Potassium Concentration and Mortality
Patients contributed a total of 1867 person-years of follow up during which time 161 death 
events were observed. Median (IQR) at-risk time was 3.2 (1.8, 4.3) years. In analyses of 
baseline dialysate potassium concentration in the overall cohort, compared to patients 
prescribed a 2mEq/L dialysate concentration, those prescribed a 1mEq/L concentration had 
higher mortality risk in case-mix, case-mix+serum potassium, case-mix+serum potassium
+potassium-binding resin, and case mix+serum potassium+potassium-modifying medication 
adjusted analyses (adjusted HRs [aHRs] [95% CI] 1.70 [1.01-2.88], 1.71 [1.01-2.90], 1.70 
[1.00-2.88], and 1.72 [1.01-2.93], respectively), whereas patients prescribed a 3mEq/L bath 
had similar mortality risk (aHR [95% CI] 0.95 [0.64-1.39], 0.94 [0.63-1.40], 0.94 
[0.63-1.39], and 0.91 [0.6-1.36], respectively) (Figure 1 and Supplementary Table 1). In 
sensitivity analyses adjusted for expanded case-mix+serum potassium+potassium-modifying 
medications covariates, point estimates for receipt of a 1mEq/L dialysate potassium 
concentration suggested higher mortality risk, although associations narrowly missed 
statistical significance: aHR (95%CI) 1.70 (0.97-2.96), p=0.06 (Supplementary Table 1).
We observed that pre-dialysis serum potassium level was an effect modifier of the 
association between dialysate potassium concentration and mortality risk. In analyses 
stratified by serum potassium, patients prescribed a 1mEq/L bath had higher mortality 
among those with serum potassium levels ≥5mEq/L in case-mix adjusted analyses 
(reference: 2mEq/L): aHR (95% CI) 2.87 (1.51-5.46). However, we did not observe a 
significant association between patients prescribed a 1mEq/L bath and mortality among 
those with serum potassium levels <5mEq/L: aHR (95% CI) 0.74 (0.27-2.07), p-
interaction=0.04. These patterns of association persisted in models incrementally adjusted 
for case-mix, case-mix+serum potassium, case-mix+serum potassium+potassium-binding 
resin, case-mix+serum potassium+potassium-modifying medication covariates (Figure 2 and 
Supplementary Table 2). Sensitivity analyses adjusted for expanded case-mix+serum 
potassium+potassium-modifying medications covariates also showed that a 1mEq/L 
dialysate potassium concentration was associated with higher mortality in patients with 
serum potassium levels ≥5mEq/L but not in those with serum potassium <5mEq/L: aHRs 
(95% CI) 2.51 (1.24-5.06) and 0.76 (0.26-2.23), respectively; p-interaction=0.04 
(Supplementary Table 2).
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In analyses of time-dependent dialysate and serum potassium concentrations adjusted for 
case-mix covariates, there was a trend between receipt of 1mEq/L dialysate potassium 
concentrations and higher mortality risk, although associations did not achieve statistical 
significance (Supplementary Table 3). Similar patterns were observed when analyses of 
time-dependent dialysate potassium concentration and mortality were stratified by time-
dependent serum potassium level (Supplementary Table 4).
Discussion
In a prospective, multi-center cohort of maintenance hemodialysis patients across Southern 
California, we observed that patients prescribed a dialysate potassium concentration of 
1mEq/L had higher mortality risk compared to those receiving a 2 or 3mEq/L dialysate 
potassium concentration bath. However, in a priori defined analyses stratified by serum 
potassium level, we found that low dialysate potassium concentrations of 1mEq/L were 
associated with higher mortality risk only among patients with high pre-dialysis serum 
potassium levels (≥5mEq/L) but not in those with low serum potassium levels (<5mEq/L). 
These observations persisted across sensitivity analyses with incremental levels of 
multivariable adjustment for case-mix covariates, serum potassium levels, potassium-binding 
resins, and potassium-modifying medications.
There has been considerable debate regarding the safety of low dialysate potassium 
concentrations particularly in the setting of high pre-dialysis serum potassium levels.[27] An 
early report by Karnik et al. and a more recent study by Pun et al. have both shown that 
receipt of low dialysate potassium concentrations (defined as 0-1mEq/L and <2mEq/L, 
respectively) were associated with higher risk of cardiac arrest among in-center 
hemodialysis patients.[11, 12] However, a study of 81,013 prevalent dialysis patients from a 
large national dialysis organization by Kovesdy et al. observed that higher dialysate 
potassium concentrations (>3mEq/L) were associated with higher mortality among those 
with elevated pre-dialysis serum potassium levels (>5mEq/L),[2] whereas an analysis of 
55,183 patients from the Dialysis Outcomes and Practice Patterns Study (DOPPS) cohort 
who were administered a dialysate potassium concentration of 2mEq/L vs. 3mEq/L showed 
no associations with all-cause mortality or cardiovascular events.[10] Most recently, Brunelli 
et al. examined hemodialysis patients from a national LDO and found an incremental 
association between higher serum-to-dialysate potassium gradients ≥3meq/L with higher 
risk of hospitalizations and emergency department visits.[17]
To our knowledge, our study is the first to show that low dialysate potassium concentrations 
are associated with higher mortality risk among patients with high serum potassium 
concentrations (≥5mEq/L) but not in those with normal serum potassium (<5mEq/L), 
supporting findings from the recent Brunelli et al. study suggesting that high serum-to-
dialysate potassium gradients may be harmful.[14, 15] While the majority of total body 
potassium exists in intracellular compartments, potassium removal during dialysis is largely 
driven by the extracellular serum-to-dialysate-potassium concentration gradient, which is 
highest in the first hour of dialysis, dissipates over treatment, and may be further attenuated 
post-dialysis due to a rebound effect (i.e., post-dialysis extracellular potassium movement).
[8] It has been suggested that rapid changes in serum potassium levels, primarily during the 
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first hour of dialysis, can lead to de-stabilization of cell membranes, QTc interval dispersion, 
ventricular ectopy, and arrhythmogenicity.[28–30]
The heterogeneous findings across studies may potentially be explained by a differential 
relationship between the serum-to-dialysate-potassium gradient with short-term vs. long-
term risk.[17] While a small serum-to-dialysate-potassium gradient among patients with 
higher serum potassium levels may bear long-term risk (i.e., potassium accumulation/
overload leading to eventual death), it is also possible that a large gradient may lead to 
malignant arrhythmias, sudden cardiac death, and hence short-term risk. Based on these 
collective data, further studies are needed to determine whether alternative methods of 
dialysis prescription (i.e., potassium profiling), pharmacotherapies (e.g., sodium zirconium 
cyclosilicate, patiromer), and dietary interventions that prevent inter-dialytic accumulation 
of serum potassium can improve the survival of hemodialysis patients.
The strengths of our study include its examination of a prospective cohort of hemodialysis 
patients who underwent protocolized collection of socio-demographic, comorbidity, 
laboratory, and medication data; longitudinal information on dialysis prescription 
characteristics; and rigorous adjudication of mortality events. However, there are several 
limitations of the study that should be noted. First, while we observed a robust association 
between baseline dialysate potassium and serum potassium levels with mortality, these 
findings do not reflect how changes in dialysate and serum potassium concentrations over 
time influence mortality. However, we found that the vast majority (~73%) of our study 
maintained the same dialysate potassium concentration during follow up. Second, as we do 
not know the clinical indications for which specific dialysate potassium concentrations were 
prescribed, it is possible that those receiving 1mEq/L dialysate potassium concentrations 
were those who were less compliant with dialysis and dietary prescriptions and with worse 
underlying ill health status. While we observed robust associations between receipt of a 
1mEq/L dialysate potassium concentration and higher mortality among patients with serum 
potassium levels ≥5mEq/L but not in those with serum potassium <5mEq/L after accounting 
for differences in pre-dialysis serum potassium levels, multiple comorbidities and nutritional 
status, we cannot exclude confounding by indication on this basis. Third, our study 
population’s observed pre-dialysis serum potassium levels were largely within a narrow 
range (4 to 6mEq/L; only 8 patients had serum potassium levels ≥6mEq/L), which may limit 
generalizability to patients with very low or high serum potassium levels. However, our 
findings do apply to the vast majority of patients in clinical practice whose serum potassium 
generally ranges between 4 and 6mEq/L. Fourth, we lacked data on cause-specific death in 
providing insights into underlying pathways towards mortality. Lastly, as with all 
observational studies, we cannot exclude the possibility of residual confounding, and our 
findings do not confirm a causal association of dialysate and serum potassium with mortality 
risk.
In conclusion, our study is the first to show that the prescription of low (1mEq/L) potassium 
dialysate concentrations is associated with higher mortality risk, particularly among 
hemodialysis patients with high pre-dialysis serum potassium concentrations, which may 
relate to large serum-to-dialysate-potassium gradients leading to rapid changes in potassium 
during the dialysis procedure. Further studies are needed to verify the risk associated with 
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rapid potassium removal during dialysis, as well as the potential role for interventions (i.e., 
potassium binding resins) obviating the need and risk of excessive potassium removal during 
dialysis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Baseline dialysate potassium concentration and all-cause mortality risk in the overall cohort 
using case-mix adjusted Cox models.
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Figure 2. 
Baseline dialysate potassium concentration and all-cause mortality, stratified according to 
pre-dialysis serum potassium level, using case-mix adjusted Cox models: Serum potassium 
<5mEq/L (Panel A) vs. serum potassium ≥ 5 mEq/L (Panel B).
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Table 1
Baseline Characteristics according to Dialysate Potassium Concentration.
DIALYSATE POTASSIUM CONCENTRATION P*
1mEq/L 2mEq/L 3mEq/L
No. of patients (%) 47 (8%) 449 (72%) 128 (21%) N/A
Age, years (Mean±SD) 50.1±15.5 54.1±14.3 57.3±14.4 0.02
Female (%) 58 44 35 0.03
Black race (%) 32 35 38 0.69
Hispanic ethnicity (%) 64 47 41 0.03
Vintage, months (Mean±SD) 71.9 ± 48.3 52.2 ± 48.5 .35.0± 36.2 <0.001
Vascular access (%)
 AVF/AVG 79 79 85 0.52
 Catheter 21 21 15
Marital status (%)
 Non-married 62 56 52. 0.28
 Married 38 43 46
 Unknown/other 0 0 2
Primary insurance (%)
 Medicare/Medicaid 77 77 67 0.18
 Private 11 10 17
 Other/Unknown 13 13 16
BMI, kg/m2 (Mean±SD) 27.5 ± 7.1 27.7 ± 6.1 28.0 ± 5.5 0.46
COMORBIDITIES
Diabetes (%) 50 52 50 0.86
CHF (%) 13 10 9 0.81
CAD (%) 13 9 13 0.34
CVA/TIA (%) 2 0 1 0.17
CVD 23 18 19 0.64
MIS (Mean±SD) 3.9± 2.0 4.5±2.9 4.6±3.1 0.64
LABORATORY RESULTS (median [IQR])
Serum Potassium (mEq/L) 5.21 (4.7, 5.6) 5.0 (4.6, 5.3) 4.7 (4.4, 5.0) <0.001
Bicarbonate (mEq/L) 23 (20, 26) 23 (21, 26) 23 (21, 25) 0.80
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DIALYSATE POTASSIUM CONCENTRATION P*
1mEq/L 2mEq/L 3mEq/L
spKt/V (single pool) 1.66 (1.54, 1.93) 1.63 (1.43, 1.86) 1.58 (1.41, 1.87) 0.37
Serum albumin (g/dL) 4.1 (3.9, 4.3) 4.0 (3.8, 4.2) 4.0 (3.9, 4.2) 0.24
nPCR (g/kg/day) 1.2 (1.0, 1.3) 1.0 (0.9, 1.2) 0.9 (0.8, 1.1) <0.001
Phosphorus (mg/dL) 5.2 (4.0, 7.1) 4.9 (4.1, 5.7) 4.7 (3.8, 5.3) 0.01
Serum creatinine (mg/dL) 10.8 (9.3, 12.7) 9.9 (7.9, 12.0) 8.2 (6.1, 10.4) <0.001
Hemoglobin (g/dL) 10.5 (9.7, 11.2) 10.7 (10.1, 11.3) 10.8 (10.3, 11.5) 0.23
BODY ANTHROPOMETRY (median [IQR])
Waist Circumference (cm) 88 (83, 99) 96 (85, 107) 97 (90, 109) 0.02
Triceps Skinfold (mm) 23 (14, 31) 17 (10, 28) 19 (12, 28) 0.12
Biceps Skinfold (mm) 14 (8, 21) 11 (6,19) 11 (6, 18) 0.16
Mid-arm muscle circumference (cm) 23 (21, 25) 24 (21, 27) 25 (22, 28) 0.25
Mid-arm circumference (cm) 31 (27, 34) 30 (27, 34) 31 (28, 35) 0.55
NIR body fat (%) 30 (20, 38) 29 (22, 38) 30 (21, 39) 0.99
MEDICATION USE (%)
Sodium polystyrene 0 <1 <1 0.84
ACEi and ARB 30 37 37 0.60
NSAIDs 19 33 32 0.15
Potassium Sparing Diuretics 0 0 <1 0.14
Other (Trimethoprim-Sulfamethoxazole, Heparin, Potassium 
supplement)
2 <1 0 0.29
Note: Categorical variables are given as percentages; continuous variables as mean±SD or median (IQR).
Abbreviations: AVF, arteriovenous fistula; AVG, arteriovenous graft; BMI, body mass index; CHF, congestive heart failure; MI, myocardial 
infarction; CAD, coronary artery disease; CVA, cerebrovascular accident; TIA, transient ischemic attack; CVD, cardiovascular disease; nPCR, 
normalized protein catabolic rate; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal anti-
inflammatory drugs.
*
P-value calculated by ANOVA, Chi-square, or Kruskal Wallis tests.
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